Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Nektar Therapeutics shares valued at $7,177 were sold by Zalevsky Jonathan on May 19 ’25. At $0.67 per share, Zalevsky Jonathan sold 10,712 shares. The insider’s holdings dropped to 305,892 shares worth approximately $0.2 million following the completion of this transaction.
Also, Wilson Mark Andrew sold 9,996 shares, netting a total of over 6,697 in proceeds. Following the sale of shares at $0.67 each, the insider now holds 314,296 shares.
Before that, ROBIN HOWARD W had sold 23,208 shares from its account. In a trade valued at $15,549, the President & CEO traded Nektar Therapeutics shares for $0.67 each. Upon closing the transaction, the insider’s holdings decreased to 23,208 shares, worth approximately $0.7 million.
As published in a research note from Jefferies on April 11, 2025, Nektar Therapeutics [NKTR] has been rated up from a Hold to a Buy and the price target has been revised to $2. Analysts at Oppenheimer upgraded the stock from ‘”a Perform”‘ to ‘”an Outperform”‘ outlook in a report released in mid March. As of January 08, 2025, B. Riley Securities has initiated its “Buy” rating for NKTR. Earlier on December 10, 2024, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for NKTR stock.
Analyzing NKTR Stock Performance
During the last five days, there has been a drop of approximately -2.94%. Over the course of the year, Nektar Therapeutics shares have dropped approximately -29.03%. Shares of the company reached a 52-week high of $1.2500 on 01/07/25 and a 52-week low of $0.4300 on 04/09/25.
Support And Resistance Levels for Nektar Therapeutics (NKTR)
According to the 24-hour chart, there is a support level at 0.6267, which, if violated, would cause prices to drop to 0.5933. In the upper region, resistance lies at 0.6767. The next price resistance is at 0.6933. RSI (Relative Strength Index) is 47.13 on the 14-day chart, showing neutral technical sentiment.
